SLC6A14 and neoplasm: Complete absence of SLC6A14 mRNA, as depicted in Figure 5A, was associated with a 41.9-month decrease in the overall survival of HCC patients compared to patients having detectable tumor SLC6A14 mRNA (p < 0.01, HR = 0.57 (0.4–0.82)).